Metabolic Syndrome
The Gut Microbiome and Heart Health: What the Evidence Shows
Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers before starting new treatments and for all medical decisions. Never delay seeking medical care based on content you have read.
These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.
In Brief
The human gut contains trillions of bacteria that ferment fibre and produce compounds entering the bloodstream, compounds that influence inflammation, insulin sensitivity, and blood vessel function, the same biology that drives metabolic syndrome. Three pathways have the strongest evidence: short-chain fatty acids (made when bacteria ferment fibre, with anti-inflammatory and insulin-sensitising effects), TMAO (made from choline and carnitine, linked to cardiovascular risk in observational studies but heavily confounded by kidney function), and bile acid signalling (which helps regulate glucose and lipid metabolism). The honest summary is that the science is real and measurable but still largely associative, while the consumer microbiome industry (stool tests and probiotic supplements marketed for heart health) has moved well ahead of the evidence. The most reliable application of what is currently known points back to fibre, dietary diversity, minimally processed foods, activity, and sleep, not to specialised products.
The human gut contains trillions of bacteria and other microorganisms that do real metabolic work. They ferment the fibre the body cannot digest, synthesise certain vitamins, and convert dietary compounds into metabolites that enter the bloodstream and reach distant organs. Some of those metabolites act on the same processes that drive metabolic syndrome: inflammation, insulin sensitivity, and the health of the cells lining blood vessels.
That overlap is why the gut microbiome has become one of the most discussed topics in cardiometabolic health, and one where commercial enthusiasm has outpaced the evidence. The underlying biology is real and measurable. The products built on top of it (stool tests offering personalised diets, probiotic supplements marketed for heart health) have generally moved faster than the evidence behind them.
The single most useful idea to carry through this article is mechanistic: when gut bacteria ferment dietary fibre, they produce short-chain fatty acids that lower inflammation and improve insulin sensitivity, and the strongest, most consistent microbiome findings in metabolic health trace back to that one process. Almost everything else in the field is more preliminary.
Articles 1 and 2 established what metabolic syndrome is and why it develops: visceral fat, insulin resistance, and the inflammatory cascade they produce. This article examines what the gut microbiome adds to that picture, which pathways are supported by good evidence, and where the science remains too early to act on. Article 4 then turns to testing.
What the Gut Microbiome Is
The human gut contains roughly 38 trillion bacterial cells representing over 1,000 species.[1] Collectively, this community performs work human cells cannot: fermenting complex carbohydrates that resist digestion, synthesising certain vitamins, and transforming dietary compounds into metabolites that enter circulation. The microbiome also includes fungi, archaea, and viruses, components that are studied less and probably underestimated.
The composition of any individual’s microbiome varies with genetics, early-life exposures, medications, diet, and environment. That variation is part of why the same dietary change can produce different metabolic responses in different people. But the microbiome operates within the broader context of body composition, physical activity, sleep, and overall metabolic health; it is one contributor, not the controlling one.
The most important conceptual shift in modern microbiome research is the move away from “good bacteria versus bad bacteria” toward microbial function. What matters most is not which species are present, but what metabolites the community produces, and whether those compounds support or undermine metabolic health. There is no single “healthy microbiome profile” that applies to everyone; healthy individuals carry very different communities, and the same person’s profile shifts with diet, illness, ageing, and medications.
This function-first view reshapes how food fits in. From a microbial standpoint, food is a set of chemical inputs the bacterial community processes, and the signals it generates in response extend beyond calorie content. Fibre provides the substrate for beneficial metabolite production. Choline and carnitine from certain foods can be converted into a compound associated with cardiovascular risk. Dietary fats influence bile acid signalling. These are the three pathways with the most evidence, and the rest of this article works through each in turn.
Short-Chain Fatty Acids: The Best-Supported Pathway
The clearest evidence for a microbiome–metabolism link comes from the compounds gut bacteria produce when they ferment dietary fibre. Articles 1 and 2 traced how visceral fat drives inflammation, insulin resistance, and endothelial dysfunction. Short-chain fatty acids (SCFAs) act on the same biology in the opposite direction: lowering inflammation, improving insulin sensitivity, and supporting the vascular lining rather than degrading it.
When gut bacteria ferment fibre, they produce SCFAs, primarily butyrate, propionate, and acetate. Fibre, in this sense, is not inert roughage; it is microbial fuel, and removing it removes the substrate for much of the microbiome’s beneficial output.
Not all fibre behaves the same way. Different fibres are fermented differently depending on their structure and the microbial community present, and whole-food sources (vegetables, fruits, legumes, whole grains, nuts, seeds) generally produce broader effects than isolated fibre supplements. A psyllium supplement is not biologically equivalent to the variety of substrates in a varied plant-based diet. Importantly, the cardiovascular benefits of dietary fibre are not solely microbiome-mediated: fibre also affects cholesterol metabolism, blood pressure, and the glucose response through direct mechanisms.[17]
- Butyrate is the primary fuel for the cells lining the colon. Beyond that local role, it helps maintain the tight junctions between intestinal cells (barrier integrity), dampens inflammatory signalling, and, in mechanistic studies, is associated with improved insulin sensitivity and release of the satiety hormone GLP-1.[2] A large metagenomic study of type 2 diabetes found reduced abundance of butyrate-producing bacteria in affected individuals.[3]
- Propionate influences glucose production in the liver, suppresses cholesterol synthesis, and stimulates satiety hormone release.[4]
- Acetate circulates at the highest concentrations of the three and affects appetite regulation, fat oxidation, and immune cell function.[5]
The table below summarises the three SCFAs and the level of evidence behind each.
| SCFA | Key metabolic effects | Clinical relevance |
| Butyrate | Barrier integrity, insulin sensitivity, anti-inflammatory signalling | Reduced in type 2 diabetes cohorts[3] |
| Propionate | Glucose regulation, satiety, cholesterol suppression | Associated with better glucose control[4] |
| Acetate | Appetite regulation, fat oxidation | Most abundant SCFA in circulation[5] |
Taken together, these compounds shift the metabolic environment toward lower inflammation and better insulin signalling, the same forces that, when they run the other way, drive endothelial dysfunction and atherosclerosis. SCFAs do not directly treat cardiovascular disease. What the evidence supports is more modest and more useful: they help shape the biological environment in which cardiovascular disease either develops or doesn’t.
TMAO: A Lesson in How to Read a Biomarker
Trimethylamine N-oxide (TMAO) is the microbiome pathway that has drawn the most cardiovascular attention, and the one that best illustrates how a single biomarker can be both genuinely interesting and easy to misinterpret.
When gut bacteria metabolise dietary choline (found in eggs, meat, and fish) and carnitine (abundant in red meat), they produce trimethylamine; the liver then oxidises it to TMAO, which enters circulation.[6,9] In animal and cell studies, TMAO promotes the early steps of plaque formation and increases platelet reactivity, and in observational human studies, higher circulating TMAO has been associated with increased risk of heart attack, stroke, and death.[7,8]
The story is more complicated than those findings alone suggest, and the complications are the most important part of this section.
Kidney function is a major confounder. TMAO is cleared by the kidneys. People with reduced kidney function have higher TMAO for reasons unrelated to diet, and reduced kidney function is itself a major cardiovascular risk factor. Much of the observed association between TMAO and cardiovascular events may reflect this confounding rather than direct vascular harm.
The fish paradox. Fish is one of the highest dietary sources of TMAO and its precursors, yet fish consumption is consistently associated with cardiovascular benefit. If TMAO straightforwardly caused cardiovascular disease, that relationship should run the other way. This is the central lesson TMAO research offers: a single biomarker, pulled out of its dietary context, rarely captures the metabolic effect of a whole food pattern.
Individual variation. Not everyone produces high TMAO on choline- and carnitine-rich diets. Bacterial composition, genetics, and overall diet all shape how much an individual generates. And whether TMAO directly damages arteries or mainly marks other risk factors remains unresolved.
TMAO can be measured commercially, but it is not part of guideline-based cardiovascular care, and there is no validated way to act on the result clinically. That is the appropriate place for it to sit: biologically interesting, mechanistically plausible, not yet clinically actionable. The broader principle applies across microbiome research: a measurable compound, separated from its dietary and metabolic context, can become clinically misleading.
Bile Acid Signalling
Bile acids are synthesised in the liver from cholesterol and help break down dietary fats. They also act as metabolic messengers, signalling molecules that help regulate glucose handling, lipid metabolism, and energy expenditure throughout the body.[10]
The microbiome shapes this signalling directly. Gut bacteria convert primary bile acids made by the liver into secondary bile acids, which then activate receptors involved in glucose homeostasis, lipid metabolism, energy expenditure, and immune function.[11] Disrupted bile acid metabolism, a common consequence of altered gut bacteria, has been correlated with insulin resistance and metabolic syndrome in observational studies.
The bile acid pathway is less clinically developed than the SCFA or TMAO pathways, but it is one of the clearest examples of microbial activity reaching well beyond digestion to influence whole-body metabolism.
The Intestinal Barrier
The intestinal lining is a single-cell-thick selective barrier. When it becomes more permeable, microbial fragments (particularly bacterial lipopolysaccharide, LPS) can cross into circulation, activate immune cells, and drive chronic low-grade inflammation.
The precise term for this is increased intestinal permeability, or intestinal barrier dysfunction. The popular phrase “leaky gut syndrome” implies a specific, well-defined diagnosis, and it is not one. Increased permeability is measurable in research settings, but there is no universally accepted clinical definition, and current evidence does not support the broad claim that most chronic symptoms are caused by it. The term has been used in wellness marketing well beyond what the science supports.
What the evidence does support is narrower: when the barrier becomes more permeable, the immune system encounters more microbial signals, which can push the body toward the same chronic low-grade inflammation that drives insulin resistance and endothelial dysfunction. This is one of the more plausible mechanistic bridges between gut biology and metabolic syndrome. Permeability also exists on a spectrum: the barrier is always somewhat permeable, and the question is how selectively it limits passage and how the immune system responds.
How Modern Diets Stress the Gut
The microbiome evolved alongside dietary patterns that bore little resemblance to modern Western diets. Looking at contemporary food through the lens of microbial biochemistry, rather than moral labels of “good” and “bad” foods, helps explain why modern eating patterns stress the gut–metabolic axis.
Highly processed foods reduce the diversity of substrates the gut ecosystem receives. They affect the microbiome through several specific mechanisms: processing removes most fermentable fibre, cutting the microbial fuel supply; engineered products expose the microbiome to a narrow range of rapidly absorbed ingredients rather than the biochemical variety of minimally processed plants; refined carbohydrates and processed fats are absorbed high in the intestine, leaving little fermentable material to reach the lower gut where most fermentation happens; and high-fat, low-fibre diets shift the bile acid pool in ways that may reduce beneficial signalling. Consistent with this, diets low in plant variety correlate with reduced gut bacterial diversity in population studies, and greater diversity generally supports a wider range of metabolite production.
Environmental exposures. The gut is also a major site of interaction with non-food inputs. Antibiotics, proton pump inhibitors, metformin, and NSAIDs can all alter microbiome composition. Emulsifiers and artificial sweeteners affect gut bacteria in experimental studies, though the clinical significance in humans varies. Human outcome data for most of these exposures remain limited.
One clarification matters here: altering the microbiome is not the same as harming it. Microbiome changes can be beneficial, adaptive, neutral, or harmful depending on context. Metformin, for instance, alters composition in ways that may actually contribute to its glucose-lowering effect. The biology is rarely as simple as “anything that changes the bacteria must be bad.”
What the Research Shows
The evidence is best read in tiers: stronger for some interventions, more preliminary for others.
Stronger evidence
- Dietary fibre. Randomised trials consistently show that increasing fibre shifts gut bacterial composition, particularly toward more SCFA-producing bacteria, and is associated with improved insulin sensitivity and lower inflammatory markers.[13] The cardiovascular benefits of high-fibre patterns are well-established independently of microbiome effects.[17]
- Plant diversity. The American Gut Project, analysing more than 15,000 stool samples, found that dietary plant diversity correlated strongly with gut bacterial diversity.[12]
- Mediterranean dietary pattern. Microbiome analyses from Mediterranean-style interventions show increases in SCFA-producing bacteria, reductions in pro-inflammatory strains, and improved metabolic markers correlating with those microbiome changes, shifts observed within weeks that confirm the microbiome is dynamic rather than fixed.[14]
Across these stronger findings, one pattern recurs: the dietary inputs that support a diverse, SCFA-producing microbial community are the same inputs associated with reduced cardiovascular risk by every other line of evidence in this field. The microbiome does not point in a different direction; it adds a mechanism for the direction already established.
Moderate evidence
- Antibiotics. Short-term exposure can temporarily alter insulin sensitivity,[15] and repeated courses across the lifespan have been associated with increased metabolic syndrome risk.[16] Diversity usually recovers within weeks, though some changes may persist. This is not an argument against necessary antibiotics but a reason for judicious prescribing.
- Exercise and sleep. Physical activity has been associated with greater microbial diversity and more SCFA-producing organisms, independent of body weight. Sleep disruption and circadian misalignment have emerging associations with microbiome shifts. The same lifestyle factors that drive cardiometabolic health appear to influence microbial signalling.
More preliminary
- Fermented foods. Studies show modest, inconsistent effects: typically temporary increases in bacterial diversity and small changes in inflammatory markers with regular consumption, diminishing when consumption stops.[18]
Most current evidence favours feeding the existing ecosystem over trying to replace it. Prebiotics (fibre compounds that serve as substrates for resident bacteria) show more consistent associations with metabolic benefit than probiotic supplements.[19] Most commercial probiotics do not permanently colonise the gut, and effects are highly strain-specific. Prebiotic-rich foods include garlic, onions, leeks, chicory, bananas, oats, asparagus, and artichokes.
Why Microbiome Studies Are Hard
Anyone following this field will notice that findings sometimes conflict sharply. There are real methodological reasons for this.
Bacterial populations vary with diet, geography, medications, sequencing methods, stool collection timing, and transit time. Two laboratories analysing the same sample with different methods can produce different results, and the same person can show different profiles in samples taken days apart. Stool samples are also imperfect proxies: they do not necessarily reflect the bacterial communities attached to the intestinal lining, which can differ substantially in composition and activity.
Many striking findings come from animal studies: germ-free mice colonised with bacteria from healthy or diseased donors. These are scientifically valuable but do not reliably translate to humans, who differ from mice in gut anatomy, immune biology, and microbial composition.
The central challenge is determining whether observed microbial changes drive metabolic disease, result from it, or both. Most current evidence is associative. Some pathways (SCFAs from fibre, TMAO from choline and carnitine) have plausible mechanisms supported by experimental data. But translating any of this into individual clinical decisions remains limited by measurement variability, the difficulty of assessing diet, confounding factors, and the field’s relative youth.
One implication deserves emphasis. Microbiome composition can shift within days in response to diet, antibiotics, or illness. Cardiovascular disease develops over years to decades. That mismatch in time scale means short-term microbiome changes, whether from a consumer test or a research study, rarely predict long-term cardiovascular outcomes the way the marketing around them implies. What matters is the cumulative pattern of microbial inputs over years, not a single snapshot.
A Note on Clinical Limitations
The microbiome is a legitimate and fast-growing area of science, and one where consumer interest has outpaced the clinical evidence. Knowing where the science stands, and where it does not, helps patients make informed decisions.
Most direct-to-consumer microbiome tests describe which bacteria are present. They do not currently provide validated guidance for improving cardiometabolic outcomes, because the science of translating composition into individual recommendations is not there yet. Probiotic claims are often strain-specific in the research but generalised in marketing: evidence for one strain in one condition rarely extends to the whole category. Personalised microbiome-based nutrition is an active research area, not a clinically validated practice. Current science is much better at explaining broad population patterns than making precise individual predictions.
Two points are worth holding onto. First, there is no established universal “healthy microbiome” profile: composition varies widely between healthy people, and what the community produces matters more than which species are present. Second, “natural” does not automatically mean beneficial in microbiome biology, and “manufactured” does not automatically mean harmful. Some fermented foods support beneficial function; some supplements do not.
The science here is interesting. Much of it is also still early, and the most reliable application of current evidence still points back toward diet, activity, and sleep rather than specialised products. Because the microbiome shifts daily and there is no single profile to perfect, it is also not worth anxious over-management: restrictive eating driven by microbiome worry tends to do more harm than good.
What Current Evidence Practically Supports
Current microbiome research supports dietary patterns already well-established in cardiovascular medicine: more minimally processed plant foods, greater dietary diversity, adequate fibre from whole-food sources, less reliance on ultra-processed foods, and Mediterranean-style eating. These are not new prescriptions; they are the same patterns that consistently appear in cardiovascular outcomes research, now with a clearer biological explanation for why they work. Many of the beneficial effects observed in research come from cumulative patterns sustained over years, not from isolated foods or short-term interventions.
What current evidence does not support: routine microbiome testing for cardiovascular risk, probiotic supplements as a substitute for dietary patterns, TMAO testing for clinical decisions, or individualised microbiome-based nutrition.
The Bottom Line
The gut microbiome influences metabolic syndrome through specific, measurable pathways (short-chain fatty acids from fibre, TMAO from choline and carnitine, bile acid signalling, and intestinal barrier function), and these converge on the same biology this series has tracked throughout: inflammation, insulin resistance, and the slow injury to blood vessels that produces cardiovascular disease. But most of the human evidence is associative, individual prediction remains unreliable, and the gap between what the microbiome contains (which bacteria are present) and what it does (which metabolites it produces) is the main reason consumer stool tests cannot yet guide cardiometabolic decisions. The practical implications are not new: fibre, dietary diversity, minimally processed foods, physical activity, and sleep support a healthier microbiome and lower cardiovascular risk at the same time.
The microbiome’s lasting contribution is likely to be explanatory rather than prescriptive: it helps explain why the same foundational patterns keep emerging as the answer across nearly every domain of cardiovascular prevention. What matters for the heart is not what a stool sample looks like this week, but the pattern of what reaches the gut over years.
Continue to Article 4: Getting Tested → Article 4 covers the practical side of metabolic syndrome detection: what standard testing captures, where standard reference ranges miss early dysfunction, and what to ask for when borderline numbers may reflect a connected pattern.
Key Terms
Bile acids: Molecules made in the liver from cholesterol that aid fat digestion and act as signalling molecules regulating glucose and lipid metabolism. Gut bacteria convert them into secondary bile acids that activate metabolic receptors.
Gut microbiome: The community of trillions of bacteria and other microorganisms in the digestive tract; influences metabolism, immunity, and inflammation.
Intestinal barrier function: The selective permeability of the intestinal lining. Barrier dysfunction (sometimes called “increased intestinal permeability”) refers to measurable changes in how effectively the gut limits passage of microbes and microbial products.
Prebiotics: Fibre compounds that serve as substrates for existing gut bacteria; found in garlic, onions, bananas, oats, and other plant foods.
Probiotics: Live bacteria consumed through fermented foods or supplements; effects are typically temporary and strain-specific.
Short-chain fatty acids (SCFAs): Compounds (butyrate, propionate, acetate) produced when gut bacteria ferment dietary fibre; associated with improved insulin sensitivity and reduced inflammation.
TMAO (Trimethylamine N-oxide): A compound produced when gut bacteria metabolise choline and carnitine from certain foods; associated with cardiovascular risk in observational studies, with interpretation substantially complicated by kidney function confounding and dietary context.
References
- Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 2016;14(8):e1002533. https://doi.org/10.1371/journal.pbio.1002533
- Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27(2):104–119. https://doi.org/10.1111/j.1365-2036.2007.03562.x
- Qin J, Li Y, Cai Z, et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012;490(7418):55–60. https://doi.org/10.1038/nature11450
- Chambers ES, Viardot A, Psichas A, et al. Effects of targeted delivery of propionate to the human colon on appetite regulation, body weight maintenance and adiposity in overweight adults. Gut. 2015;64(11):1744–1754. https://doi.org/10.1136/gutjnl-2014-307913
- Frost G, Sleeth ML, Sahuri-Arisoylu M, et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun. 2014;5:3611. https://doi.org/10.1038/ncomms4611
- Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med. 2013;368(17):1575–1584. https://doi.org/10.1056/NEJMoa1109400
- Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63. https://doi.org/10.1038/nature09922
- Heianza Y, Ma W, Manson JE, et al. Gut microbiota metabolites and risk of major adverse cardiovascular disease events and death: a systematic review and meta-analysis of prospective studies. J Am Heart Assoc. 2017;6(7):e004947. https://doi.org/10.1161/JAHA.116.004947
- Koeth RA, Wang Z, Levison BS, et al. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–585. https://doi.org/10.1038/nm.3145
- Wahlström A, Sayin SI, Marschall HU, Bäckhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016;24(1):41–50. https://doi.org/10.1016/j.cmet.2016.05.005
- Chiang JY. Bile acids: regulation of synthesis. J Lipid Res. 2009;50(10):1955–1966. https://doi.org/10.1194/jlr.R900010-JLR200
- McDonald D, Hyde E, Debelius JW, et al. American Gut: an open platform for citizen science microbiome research. mSystems. 2018;3(3):e00031–18. https://doi.org/10.1128/mSystems.00031-18
- So D, Whelan K, Rossi M, et al. Dietary fiber intervention on gut microbiota composition in healthy adults: a systematic review and meta-analysis. Am J Clin Nutr. 2018;107(6):965–983. https://doi.org/10.1093/ajcn/nqy041
- Ghosh TS, Rampelli S, Jeffery IB, et al. Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status. Gut. 2020;69(7):1218–1228. https://doi.org/10.1136/gutjnl-2019-319654
- Reijnders D, Goossens GH, Hermes GD, et al. Effects of gut microbiota manipulation by antibiotics on host metabolism in obese humans: a randomized double-blind placebo-controlled trial. Cell Metab. 2016;24(1):63–74. https://doi.org/10.1016/j.cmet.2016.06.016
- Cox LM, Blaser MJ. Antibiotics in early life and obesity. Nat Rev Endocrinol. 2015;11(3):182–190. https://doi.org/10.1038/nrendo.2014.210
- Reynolds A, Mann J, Cummings J, et al. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. Lancet. 2019;393(10170):434–445. https://doi.org/10.1016/S0140-6736(18)31809-9
- Wastyk HC, Fragiadakis GK, Perelman D, et al. Gut-microbiota-targeted diets modulate human immune status. Cell. 2021;184(16):4137–4153. https://doi.org/10.1016/j.cell.2021.06.019
- Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491–502. https://doi.org/10.1038/nrgastro.2017.75